Viking Therapeutics (VKTX): Assessing an Expensive Valuation After a Recent Pullback in the Share Price
Viking Therapeutics (VKTX) has experienced a recent pullback in its share price after a significant run, prompting investors to reassess its valuation. Despite the slide, analyst targets still suggest substantial upside, but the stock trades at a high price-to-book ratio of 5.7 times, which is expensive compared to the broader biotech industry average. While the company is still loss-making and without significant near-term revenue, this premium is attributed to its clinical pipeline and management, raising questions about whether the market has adequately factored in future growth or if the valuation is stretched.
Viking Therapeutics (VKTX) deemed 'extremely attractive' and undervalued by Canaccord, cited as leader in obesity clinical development
Canaccord Genuity has initiated coverage on Viking Therapeutics (VKTX), rating it 'Buy' and calling it "extremely attractive" and undervalued. The firm believes Viking is a frontrunner in obesity clinical development with promising drug candidates VK2735 and VK2809. Canaccord anticipates significant potential for Viking to become a major player in the obesity market.
With 65% Ownership of the Shares, Viking Therapeutics, Inc. (NASDAQ:VKTX) Is Heavily Dominated by Institutional Owners
Institutional investors own 65% of Viking Therapeutics, Inc. (NASDAQ:VKTX), giving them significant influence over the company's share price. The Vanguard Group, Inc., FMR LLC, and BlackRock, Inc. are among the largest institutional shareholders, collectively owning a substantial portion of the company. Despite the strong institutional presence, insiders have been selling shares, and the general public holds a 32% stake.
1 Bold Prediction for Viking Therapeutics in 2026
The article predicts that Viking Therapeutics (NASDAQ: VKTX) will be a takeover candidate in 2026 due to the high takeover activity in the anti-obesity drug market and the potential value in its product pipeline. Despite some initial concerns during trials for its oral GLP-1/GIP agonist, VK2735, the company's treatment showed strong efficacy, suggesting a larger pharmaceutical company might find its pipeline attractive and be better equipped to manage complex clinical trials.
Viking Therapeutics (VKTX) Deemed ‘Extremely Attractive’ and Undervalued by Canaccord, Cited as Leader in Obesity Clinical Development
Canaccord has reiterated its "Buy" rating on Viking Therapeutics (VKTX) and raised its price target, calling the company "extremely attractive" and undervalued due to its advanced obesity pipeline. The company is excelling in clinical development, particularly with its dual GLP-1/GIP receptor agonist VK2735, despite a significant increase in net loss driven by clinical trial expenses. Positive Phase 2 results for VK2735 and progress in Phase 3 trials highlight the company's strong position in the obesity therapeutic area.
37,104 Shares in Viking Therapeutics, Inc. $VKTX Purchased by Marex Group plc
Marex Group plc has purchased 37,104 shares of Viking Therapeutics, Inc. (NASDAQ:VKTX) valued at approximately $983,000, establishing a new position in the company during the second quarter. This move comes as other institutional investors have also adjusted their stakes in the biotechnology firm. Despite insider selling, analysts maintain a "Moderate Buy" consensus for Viking Therapeutics, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders.
683 Capital Management LLC Trims Stock Position in Viking Therapeutics, Inc. $VKTX
683 Capital Management LLC reduced its stake in Viking Therapeutics (NASDAQ:VKTX) by 16.7% in Q2, selling 51,000 shares and retaining 254,000 shares valued at approximately $6.73 million. Analysts generally have a "Moderate Buy" rating on the stock with an average price target of $87.14, while some firms have raised targets to the $102-$105 range. Recent insider sales by the CFO and COO amounted to 111,359 shares worth about $3.93 million, though institutions hold a significant 76.03% of the stock.
Is Early VANQUISH-1 Completion And VK2735 Progress Altering The Investment Case For Viking Therapeutics (VKTX)?
Viking Therapeutics has accelerated its obesity drug development, completing Phase 3 VANQUISH-1 enrollment ahead of schedule and advancing VK2735 into Phase 3. This progress tightens the investment focus on their obesity franchise, yet investor expectations remain polarized due to funding needs, competitive pressures, and significant valuation discrepancies highlighted by mixed options activity. The company, currently without revenue and widening losses, faces a critical period as it moves towards product approval.
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street
Viking Therapeutics (VKTX) is considered a strong buy by Wall Street analysts due to significant progress in its obesity drug development. H.C. Wainwright reaffirmed its Buy rating and $102 price target after the company completed enrollment for its Phase 3 VANQUISH-1 obesity study ahead of schedule. The company is advancing VK2735 into Phase III trials for a subcutaneous formulation, and its cash reserves are robust enough to accelerate pipeline development.
This is why Viking Therapeutics, Inc. (VKTX) is a Strong Buy on Wall Street
Viking Therapeutics, Inc. (NASDAQ:VKTX) is considered a strong buy by Wall Street analysts due to its progress in obesity treatment trials. The company recently completed enrollment for its Phase 3 VANQUISH-1 obesity study ahead of schedule and expects to complete enrollment for the VANQUISH 2 study by early 2026. With $700 million in cash reserves, Viking Therapeutics is well-positioned to advance its pipeline in metabolic and endocrine diseases.
Looking At Viking Therapeutics's Recent Unusual Options Activity
High-rolling investors have shown unusual options activity in Viking Therapeutics (NASDAQ: VKTX). Analysts detected 13 options trades with mixed sentiment, highlighting a potential price window of $30.0 to $50.0. The article also provides an overview of Viking Therapeutics's biopharmaceutical focus and its current market standing with a consensus target price of $107.0 from one analyst.
460,415 Shares in Viking Therapeutics, Inc. $VKTX Acquired by Jump Financial LLC
Jump Financial LLC recently acquired a new stake of 460,415 shares in Viking Therapeutics, Inc. (NASDAQ:VKTX) valued at approximately $12.2 million during the second quarter. This move is part of broader institutional interest, with other firms like Norges Bank and Raymond James Financial also modifying their positions in the biotechnology company. Despite some insider selling and a recent earnings miss, analysts maintain a "Moderate Buy" consensus rating with an average price target of $87.14 for VKTX.
1. Viking Therapeutics (VKTX): Valuation Check After Faster-Than-Expected Enrollment in Key Obesity Drug Trial
Viking Therapeutics (VKTX) has completed patient enrollment for its Phase 3 obesity drug trial (VK2735) ahead of schedule, indicating strong demand. While the stock has seen a choppy year and a negative year-to-date return, its three-year shareholder return of 947.6% highlights growing investor confidence in its obesity pipeline. The article examines whether VKTX is undervalued given its Price to Book ratio, comparing it to broader biotech and closer peer groups.
Norges Bank Takes $46.85 Million Position in Viking Therapeutics, Inc. $VKTX
Norges Bank has acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX) during the second quarter, purchasing 1,767,777 shares valued at approximately $46.85 million, which represents a 1.57% stake in the biotechnology company. This institutional investment comes amidst recent insider selling by COO Marianna Mancini and CFO Greg Zante, who each sold 6,185 shares for $35.00, totaling over $216,000 each. Despite the insider sales, analysts maintain a "Moderate Buy" rating for VKTX with a consensus price target of $87.14.
Assessing Viking Therapeutics (VKTX) Valuation After Recent Share Price Recovery
Viking Therapeutics (VKTX) has seen a significant share price rebound recently, though its one-year return remains negative. The company's valuation, particularly its Price-to-Book ratio of 5.8x, suggests it is overvalued compared to the US biotech industry average, indicating high investor expectations for future breakthroughs despite inherent risks. Investors are encouraged to conduct their own research and consider potential risks.
Viking Therapeutics Meets 80-Plus Relative Strength Rating Benchmark
Viking Therapeutics (VKTX) recently saw its Relative Strength Rating upgraded from 75 to 81, signifying strong share price performance against other stocks. This upgrade indicates that Viking Therapeutics has met the benchmark of an 80-plus RS Rating, a key metric for investors evaluating stock momentum. The company's stock has been highlighted in relation to other biotech news, particularly concerning FDA regulatory changes and developments in weight-loss medications.
What's Up With The Jump In Viking Therapeutics Stock?
Viking Therapeutics (NASDAQ: VKTX) shares are trading higher, benefiting from the broader excitement in the obesity treatment sector and recent positive clinical trial developments. The company rapidly completed patient enrollment for its Phase 3 VANQUISH-1 trial, exceeding expectations and indicating strong interest in new obesity treatments. This momentum, alongside intense competition between Eli Lilly and Novo Nordisk in the GLP-1 market, is drawing investor attention to emerging players like Viking.
Viking Therapeutics to Participate at the Piper Sandler 37th Annual Healthcare Conference
Viking Therapeutics, Inc., a biopharmaceutical company focused on metabolic and endocrine disorders, will participate in the Piper Sandler 37th Annual Healthcare Conference. The company will have management present in a fireside chat and hold investor meetings between December 2-4, 2025, in New York City. Viking will provide updates on its clinical programs, including VK2735 and VK2809, which address metabolic and lipid disorders.
Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-1 Trial of VK2735
Viking Therapeutics has completed enrollment in its Phase 3 VANQUISH-1 trial for subcutaneous VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment, ahead of schedule and above target. The trial has enrolled approximately 4,650 adults with obesity or who are overweight and will assess the efficacy and safety of VK2735 over 78 weeks. This follows positive Phase 2 VENTURE study results, and Viking is also conducting the VANQUISH-2 study for patients with type 2 diabetes and obesity.
Viking Therapeutics (NASDAQ:VKTX) Shares Gap Down – Here’s Why
Viking Therapeutics (VKTX) shares recently gapped down, closing with a 3.5% decrease. The article details the company's financial metrics and highlights recent adjustments to institutional holdings in the biotechnology firm. It also provides an overview of Viking Therapeutics' focus on developing novel therapies for metabolic and endocrine disorders.
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key Facts - sharewise.com
Viking Therapeutics, Inc. (VKTX) saw its stock dip by 3.44% to $33.54, underperforming the broader market gains. Despite the recent dip, the company's shares have risen 33.37% over the last month, outperforming the Medical sector and the S&P 500. Investors are looking forward to the upcoming earnings report on October 22, 2025, with projected EPS of -$0.7 and a Zacks Rank of #4 (Sell).
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer - Insider Monkey
Viking Therapeutics (VKTX) received Buy ratings from Oppenheimer and H.C. Wainwright, with price targets of $100 and $102 respectively. Analysts cited the company's strong market position due to competitive efficacy and safety data from its GLP-1 programs, positioning it as a strong candidate for M&A. Despite a competitive landscape, analysts remain optimistic about Viking Therapeutics' growth prospects as a clinical-stage company developing therapies for metabolic and endocrine disorders.
Viking Therapeutics (VKTX) Receives a Buy from Oppenheimer
Oppenheimer has given Viking Therapeutics (VKTX) a Buy rating, citing the company's strong competitive efficacy and safety data from its GLP-1 programs. An H.C. Wainwright analyst also reiterated a Buy rating with a $102 price target, believing these programs position VKTX as a promising candidate for mergers and acquisitions despite competitive challenges. The company develops therapies for metabolic and endocrine disorders.
9 Best Healthcare Stocks with the Highest Upside - Insider Monkey
This article highlights Viking Therapeutics, Inc. (NASDAQ:VKTX) as one of the best healthcare stocks with the highest upside, detailing bullish analyst ratings and price targets. Analysts praise the company's strong pipeline and competitive efficacy in metabolic and endocrine disorders. The article also touches on broader investment opportunities in AI and energy infrastructure.
Earnings Preview: VKTX to Report Financial Results Post-market on October 22 - 富途牛牛
Viking Therapeutics (VKTX.US) is scheduled to release its financial results post-market on October 22 ET. Analysts estimate the company to report $0.00 revenue and an EPS of $-0.698 for Q3 2025. The company will likely host a conference call to discuss results and operational performance.
Viking Therapeutics (VKTX): Assessing Valuation as VK2735 Advances Through Late-Stage Obesity Drug Trials
Viking Therapeutics (VKTX) is progressing its dual GIP/GLP-1 receptor agonist, VK2735, with the injectable form in Phase 3 and the oral version in Phase 2 trials, generating significant investor interest. Despite a recent share price surge of 45.8% over the past month, the company's valuation—a price-to-book ratio of 5x—is considered reasonable compared to peers but expensive against the broader US Biotech industry, suggesting market expectations are driven by future potential rather than current profitability. Investors are closely watching for signs of sustainable turnaround and the resolution of clinical trial outcomes.
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
Viking Therapeutics (NASDAQ: VKTX) is set to release its financial results for the third quarter of 2025 after market close on Wednesday, October 22, 2025. The company will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss these results and provide general corporate updates. A replay of the call will be available until October 29, 2025.
Viking Therapeutics to Report Financial Results for Third Quarter 2025 on October 22, 2025
Viking Therapeutics (NASDAQ: VKTX) will release its financial results for the third quarter of 2025 on October 22, 2025, after market close. The company will also host a conference call to discuss these results and provide general corporate updates. Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders, with programs including VK2735 for obesity and VK2809 for NASH and NAFLD.
Q3 2025 Results on Oct. 22 — Viking Therapeutics to Host Conference Call and Webcast - Stock Titan
Viking Therapeutics (NASDAQ: VKTX) will release its third-quarter 2025 financial results on Wednesday, October 22, 2025, after market close. The company will host a conference call and webcast at 4:30 p.m. Eastern Time the same day to discuss the results and provide corporate updates. Investors can participate via phone or webcast, with replays available for a limited time.
Will Progress in VK2735 Weight Loss Trials Change Viking Therapeutics' (VKTX) Narrative? - simplywall.st
Viking Therapeutics has revealed significant progress in trials for its weight loss drug candidate, VK2735, showing promising results for both injectable and oral forms. This development enhances Viking's position in the nearly US$100 billion obesity market and could make it an acquisition target for larger pharmaceutical companies. While this could drive short-term share movement due to potential partnerships, the company still faces fundamental risks including a lack of revenue and persistent losses, trading at a premium to its sector peers.
Will Progress in VK2735 Weight Loss Trials Change Viking Therapeutics' (VKTX) Narrative? - simplywall.st
Viking Therapeutics has announced significant progress in late-stage clinical trials for its weight loss drug candidate, VK2735, which could position the company to challenge major industry players and become a potential acquisition target. While this progress creates optimism and potential for short-term share movement, investors need to consider the company's ongoing lack of revenue, unprofitability, and trading at a premium to sector peers. The long-term outlook will be heavily influenced by future clinical news, regulatory communications, and potential deal activity.
Viking Therapeutics, Inc. (VKTX) Registers a Bigger Fall Than the Market: Important Facts to Note - sharewise.com
Viking Therapeutics, Inc. (VKTX) shares fell 2.54% to $33.05, underperforming the broader market. Despite this daily drop, the company's stock has risen over 40% in the past month, significantly outpacing the Medical sector and S&P 500. Analysts project a substantial EPS decrease for the upcoming quarter and full year, although recent estimate revisions show some optimism.
United States Adrenoleukodystrophy Treatment Market is expected to reach US$ 673.03 Million by 2031 | Top key players - Bluebird Bio Inc., Viking Therapeutics, NeuroVia.
The United States Adrenoleukodystrophy (ALD) Treatment Market is projected to reach US$ 673.03 million by 2031, growing at a CAGR of 9.6% from 2024-2031. This growth is driven by advancements in gene therapy, increasing awareness leading to early diagnosis, and supportive government initiatives. Key players in this market include Bluebird Bio Inc., Viking Therapeutics, and NeuroVia.
Viking Therapeutics, Inc. $VKTX Shares Acquired by Blair William & Co. IL - MarketBeat
Blair William & Co. IL increased its stake in Viking Therapeutics (NASDAQ:VKTX) by 6.9% in Q2, now owning 330,007 shares valued at $8.75 million. Viking Therapeutics holds a consensus "Moderate Buy" rating with a target price of $86.42, despite missing Q2 earnings estimates with a loss of ($0.58) per share. Other institutional investors also adjusted their holdings in the biotechnology company.
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics announced positive Phase 1 trial data for its oral weight-loss drug, an oral GLP-1 medication. The drug led to an average weight loss of 8.2% in a month at a 100 mg dose. Despite initially surging, the company's stock later traded down as investors locked in recent gains.
Viking Therapeutics Announces Results from Phase 1b Clinical Trial of VK0214 in Patients with X-ALD
Viking Therapeutics announced positive results from its Phase 1b clinical trial of VK0214 in patients with X-linked adrenoleukodystrophy (X-ALD). The study showed VK0214 was safe, well-tolerated, and significantly reduced very long-chain fatty acids (VLCFAs) and other plasma lipids compared to placebo. These findings indicate a potential new therapeutic approach for the rare metabolic disorder X-ALD.
Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735
Viking Therapeutics announced positive results from its Phase 1 clinical trial of an oral tablet formulation of VK2735, a dual GLP-1/GIP receptor agonist, for metabolic disorders like obesity. The study showed up to 5.3% mean weight loss from baseline after 28 days, with the drug being safe and well-tolerated with low rates of GI-related adverse events. Following these results, the company plans to initiate a Phase 2 trial for oral VK2735 in obesity during the second half of 2024.
Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares
Viking Therapeutics announced the closing of its underwritten public offering of 7,441,650 shares of common stock at $85.00 per share, including the full exercise of the underwriters' option to purchase additional shares. The offering generated gross proceeds of approximately $632.5 million, which Viking intends to use for the continued development of its VK2809, VK2735, and VK0214 programs, as well as general research and development, working capital, and corporate purposes. Morgan Stanley, Leerink Partners, William Blair, Raymond James, Stifel, and Truist Securities acted as joint book-running managers.
Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock
Viking Therapeutics announced the pricing of its underwritten public offering of 6,471,000 shares of common stock at $85.00 per share, expecting to raise approximately $550.0 million. The company has also granted underwriters a 30-day option to purchase additional shares. Proceeds are intended for the continued development of its VK2809, VK2735, and VK0214 programs, as well as general research and development, working capital, and corporate purposes.
Viking Therapeutics stock gets boost from positive news that obesity drugs reduced risk of heart attacks and strokes
Viking Therapeutics' stock rose following positive news regarding obesity drugs reducing the risk of cardiovascular events, specifically related to Novo Nordisk's treatments. Viking Therapeutics (VKTX) is developing its own GLP-1 receptor agonists in both injectable and oral forms for obesity and diabetes, with data expected later this year. This development has generated excitement for Viking's ongoing programs.
Viking Therapeutics Presents Preclinical Data on Novel Dual GLP-1/GIP Agonists at ObesityWeek® 2021
Viking Therapeutics (NASDAQ: VKTX) presented preclinical data at ObesityWeek 2021 on novel dual GLP-1/GIP agonists, demonstrating significant weight loss of up to 28% and improved metabolic profiles in diet-induced obese mice. These results surpassed those of semaglutide and were comparable to tirzepatide, supporting the advancement of their internal development program towards a Phase 1 clinical trial. CEO Brian Lian highlighted the compounds' potential to enhance treatment options for metabolic disorders.
Viking Therapeutics Announces Senior Management Team Appointments
Viking Therapeutics announced the promotions of Greg Zante to Chief Financial Officer and Marianne Mancini to Chief Operating Officer. These appointments recognize their significant contributions to the company's success in advancing its pipeline of therapies for metabolic and endocrine disorders and executing a sound financial strategy. Both individuals bring extensive experience from the biotechnology and pharmaceutical industries to their new leadership roles.
Viking Therapeutics to Participate in Upcoming Investor Conferences
Viking Therapeutics announced its participation in two upcoming investor conferences: the 2020 Jefferies Global Healthcare Conference and the Raymond James Human Health Innovation Conference. The company's management will deliver corporate presentations and engage in one-on-one meetings at both virtual events, with a panel discussion on NASH also scheduled for the Raymond James conference. Webcasts of presentations will be available for investors.
VKTX: Presentation of Full Data Set for VK5211 Phase 2 Trial…
Viking Therapeutics presented full data from its Phase 2 clinical trial of VK5211 for hip fracture patients at the ASBMR 2018 Annual Meeting. The results showed statistically significant increases in lean body mass and favorable trends in functional performance, with no drug-related serious adverse events. This has led Zacks SCR to increase the probability of approval for VK5211 to 70% and raise Viking's valuation to $28 per share, identifying the stock as a top small-cap biotech pick.
Madrigal Pharma shares skyrocket 145% on positive results for liver disease therapy
Madrigal Pharmaceuticals Inc. saw its shares jump as much as 145% after announcing positive results from a phase 2 clinical trial for its liver disease therapy, MGL-3196. The drug, targeting non-alcoholic steatohepatitis (NASH), achieved statistically significant results for several endpoints at week 36. This news also impacted rival companies in the NASH treatment space, causing their shares to decline.
VKTX: Enrollment of Phase 2 Trial of VK2809 Nearing Completion
Viking Therapeutics (NASDAQ:VKTX) is nearing completion of enrollment for its Phase 2 trial of VK2809 for fatty liver disease, with topline results expected in the second half of 2018. The company also announced positive Phase 2 results for VK5211 in hip fracture recovery and is preparing for a Phase 3 study and potential partnership. Additionally, IND-enabling studies are underway for VK0214 for X-ALD, and the company reported Q1 2018 financial results, indicating sufficient capital into 2020.
Viking announces new preclinical results for VK5211
Viking Therapeutics announced new preclinical data for VK5211, an orally available SARM, showing robust weight gains and effective weight maintenance in primates over a 13-week study period. The findings support VK5211's potential for stimulating muscle and bone formation and are consistent with previous human Phase 1 study data, leading to an ongoing Phase 2 trial in hip fracture patients.
